Form 4 for DYN Dyne Therapeutics, Inc.
Accepted 2024-12-06 00:00:00 ET · period of report 2024-12-04 · accession 0000950170-24-134072 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-12-06 | 2024-12-04 | DYN | Cox John | CEO, Pres, Dir | A - Grant | $0.00 | +145.3K | 150.3K | +2,906% | $0 |
| D | 2024-12-06 | 2024-12-04 | DYN | Cox John | CEO, Pres, Dir | A - Grant | $0.00 | +232.1K | 232.1K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-04 | A | A | 145,300 | $0.00 | 150,300 | D | — | — | (F1) Consists of shares of Common Stock issuable under 145,300 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 4, 2025. (F2) Includes 145,300 unvested RSUs. |
| 2 | Derivative | Stock option (right to buy) | 2024-12-04 | A | A | 232,100 | $0.00 | 232,100 | D | $29.44 · — to 2034-12-03 | 232,100 Common Stock | (F4) This option was granted on December 4, 2024. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 4, 2028. |